BACKGROUND: National Institute for Clinical Excellence (NICE) guidelines recommend discharging asymptomatic breast care patients 3 years after diagnosis. A role for General Practitioners (GPs) and breast care nurses is proposed, together with skills training, but it remains unclear for how long breast cancer patients should be followed up, what tests should be done, and who should be conducting the follow-up. We therefore surveyed Breast Cancer Specialists. DESIGN: A 20-point questionnaire was sent to 562 Specialists registered in the Cancer Research Clinical Trials Unit database, with questions on case-load, perceptions of follow-up, local policy and opinions on greater primary care involvement. RESULTS: The most commonly acknowledged purpose of follow-up was detection of treatment-related morbidity. Eighty four percent of respondents adhered to a locally developed protocol with only 9% conforming to NICE guidelines. The median follow-up was 5 years. Significant factors predicting delayed discharge were younger age (P < or = 0.0001); poorer Nottingham Prognostic Index (P = 0.003); treatment factors (P = 0.002); and patient risk factors (P = 0.003). Centres with higher case-loads (>200/year) were more likely to discharge earlier. Reduced workload was perceived as the main benefit of discharge, while lack of GP oncological experience and loss of outcome data were concerns. CONCLUSIONS: Specialists favour a risk adjusted discharge strategy and increased oncology infrastructure in primary care.
BACKGROUND: National Institute for Clinical Excellence (NICE) guidelines recommend discharging asymptomatic breast care patients 3 years after diagnosis. A role for General Practitioners (GPs) and breast care nurses is proposed, together with skills training, but it remains unclear for how long breast cancerpatients should be followed up, what tests should be done, and who should be conducting the follow-up. We therefore surveyed Breast Cancer Specialists. DESIGN: A 20-point questionnaire was sent to 562 Specialists registered in the Cancer Research Clinical Trials Unit database, with questions on case-load, perceptions of follow-up, local policy and opinions on greater primary care involvement. RESULTS: The most commonly acknowledged purpose of follow-up was detection of treatment-related morbidity. Eighty four percent of respondents adhered to a locally developed protocol with only 9% conforming to NICE guidelines. The median follow-up was 5 years. Significant factors predicting delayed discharge were younger age (P < or = 0.0001); poorer Nottingham Prognostic Index (P = 0.003); treatment factors (P = 0.002); and patient risk factors (P = 0.003). Centres with higher case-loads (>200/year) were more likely to discharge earlier. Reduced workload was perceived as the main benefit of discharge, while lack of GP oncological experience and loss of outcome data were concerns. CONCLUSIONS: Specialists favour a risk adjusted discharge strategy and increased oncology infrastructure in primary care.
Authors: Erica L Mayer; Adrienne B Gropper; Bridget A Neville; Ann H Partridge; Danielle B Cameron; Eric P Winer; Craig C Earle Journal: J Clin Oncol Date: 2011-12-12 Impact factor: 44.544
Authors: Ruth A Lewis; Richard D Neal; Nefyn H Williams; Barbara France; Maggie Hendry; Daphne Russell; Dyfrig A Hughes; Ian Russell; Nicholas S A Stuart; David Weller; Clare Wilkinson Journal: Br J Gen Pract Date: 2009-07 Impact factor: 5.386
Authors: Heather B Neuman; Nicole M Steffens; Nora Jacobson; Amye Tevaarwerk; Bethany Anderson; Lee G Wilke; Caprice C Greenberg Journal: Ann Surg Oncol Date: 2015-10-16 Impact factor: 5.344
Authors: Robin Z Hayeems; Fiona A Miller; Carolyn J Barg; Yvonne Bombard; Pranesh Chakraborty; Beth K Potter; Sarah Patton; Jessica Peace Bytautas; Karen Tam; Louise Taylor; Elizabeth Kerr; Christine Davies; Jennifer Milburn; Felix Ratjen; Astrid Guttmann; June C Carroll Journal: Can Fam Physician Date: 2021-06 Impact factor: 3.275
Authors: Carriene Roorda; Annette J Berendsen; Feikje Groenhof; Klaas van der Meer; Geertruida H de Bock Journal: Support Care Cancer Date: 2012-10-04 Impact factor: 3.603
Authors: D M Greenfield; K Absolom; C Eiser; S J Walters; G Michel; B W Hancock; J A Snowden; R E Coleman Journal: Br J Cancer Date: 2009-07-28 Impact factor: 7.640
Authors: K Absolom; C Eiser; G Michel; S J Walters; B W Hancock; R E Coleman; J A Snowden; D M Greenfield Journal: Br J Cancer Date: 2009-07-28 Impact factor: 7.640